Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and...
November 13 2017 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical
company focused on the development of therapeutics for central
nervous system (CNS) disorders, announced that Andrew Satlin M.D.
has joined the company as Executive Vice President and Chief
Medical Officer. Dr. Satlin brings broad experience to the Company
with over 20 years of industry experience in all phases of drug
development in multiple therapeutic areas, including neurology and
psychiatry, as well as cardiovascular and metabolic disorders. Dr.
Satlin has extensive expertise in the design and conduct of
clinical trials in Alzheimer’s disease, Parkinson’s disease,
epilepsy, schizophrenia, depression, anxiety, heart failure and
hypertension.
Dr. Satlin spent 9 years at Eisai, most recently serving as
Executive Vice-President, Global Head of Medicine Creation
Strategy, Neurology Business Group. Before joining Eisai, he spent
11 years at Novartis in positions of increasing responsibility,
including leadership of the Neurosciences regulatory group. Prior
to joining Novartis Dr. Satlin was an Assistant Professor of
Psychiatry at Harvard Medical School. Dr. Satlin was also the
Director of Geriatric Psychiatry and established a dementia clinic
at McLean Hospital in Massachusetts. Dr. Satlin received his
medical degree from Harvard Medical School and completed his
residency in psychiatry and fellowship in geriatric psychiatry at
McLean Hospital. Dr. Satlin received his bachelor's degree from
Yale University.
“We are excited to welcome Dr. Satlin as we continue to expand
our team. Andy is a respected industry leader who strengthens our
expertise in CNS drug development, and we look forward to working
together as we continue the development of lumateperone and our
pipeline,” said Dr. Sharon Mates, Chairman and CEO of
Intra-Cellular Therapies.
“I am enthusiastic about joining the team at Intra-Cellular
Therapies at this important time in the development of
lumateperone. I look forward to the opportunity to support its
succesful registration, and to help advance a pipeline of novel
compounds addressing unmet medical needs in both psychiatry and
neurology,” stated Dr. Satlin.
About Intra-Cellular TherapiesIntra-Cellular
Therapies is developing novel drugs for the treatment of
neuropsychiatric and neurodegenerative diseases and diseases of the
elderly, including Parkinson's and Alzheimer's disease. The Company
is developing its lead drug candidate, lumateperone (also known as
ITI-007), for the treatment of schizophrenia, bipolar disorder,
behavioral disturbances in patients with dementia, including
Alzheimer's disease, depression and other neuropsychiatric and
neurological disorders. Lumateperone, a first-in-class molecule, is
in Phase 3 clinical development for the treatment of schizophrenia,
bipolar depression and agitation associated with dementia,
including Alzheimer's disease. The Company is also utilizing its
phosphodiesterase (PDE) platform and other proprietary chemistry
platforms to develop drugs for the treatment of CNS and other
disorders. The lead molecule in the Company's PDE1 portfolio,
ITI-214, is in development for the treatment of symptoms associated
with Parkinson's disease.
CONTACT:Intra-Cellular Therapies, Inc.Juan Sanchez, M.D.Vice
President, Corporate Communications and Investor
Relations646-440-9333
Burns McClellan, Inc.Lisa BurnsJustin Jackson
(Media)jjackson@burnsmc.com212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024